We are pleased to offer a 15% discount on selected Hepatitis and HIV Rapid Labs Compact ELISA Tests. Our high quality Compact ELISA tests offer consistent and reliable results at an affordable price, packaged to reduce the cost of shipping. Please contact us at info@rapidlabs.co.uk to place an order. This offer is available whilst stocks last.

ELISA
Description
Cat. No.
Expiry Date
Standard Price
Discounted Price (15%)
HBsAg
Hepatitis B Surface Antigen 96T
E-102196
May 2020
£39.98
($51.17)
£33.98
($43.49)
HCV 
Hepatitis C Virus 96T
E-103196
Aug 2020
£18.62
($23.83)
£15.82
($20.25)
HIV-1/2 O 
Human Immunodeficiency Virus Types 1 & 2 (Group O Antigen) 96T
E-101196
May 2020
£12.64
($16.18)
£10.74
($13.75)
HIV-1/2 O Ab/Ag
Human Immunodeficiency Virus Types 1 & 2 (Group O Antigen and Antibody) 96T
E-128196
Feb 2020
£18.62
($23.83)
£15.83
($20.26)

 

HBsAG ELISA

HBsAg is one of the earliest markers that appear in the blood following infection with Hepatitis B virus (HBV).1 This infection of the liver is transmitted through sexual contact, blood borne exposure, transmission from mother to child during delivery, sharing of objects that pierce the skin, child-to-child and household contact. The four major HBsAg subtypes include adw, adr, ayw, and ayr, all sharing the common determinant ‘a’. The HBV infection causes a wide variety of liver damage such as acute self-limiting infection, fulminating hepatitis, chronic hepatitis with progression to cirrhosis and liver failure, and asymptomatic chronic carrier state. In HBV infected people, the virus persists for the rest of their lives and can be passed on to others, making it a global public health problem.

Infection with HBV results in the appearance of a number of serological markers and one of the first of such markers is Hepatitis B Surface Antigen (HBsAg). HBsAg appears 1-10 weeks after exposure and before biochemical evidence of liver disease or jaundice.2,3 Three weeks after the onset of acute hepatitis almost half of the patients will still be positive for HBsAg. In the chronic carrier state, HBsAg persists for 6-12 months with no seroconversion to the corresponding antibodies. Therefore, screening for HBsAg is highly recommended for all donors, pregnant women and people in high-risk groups.

The HBsAg EIA Test Kit is a third generation immunoassay for the qualitative detection of the presence of Hepatitis B Surface Antigen in serum or plasma specimen. The test utilizes monoclonal antibodies to selectively detect various subtypes of HBsAg in serum or plasma.

Incubation Time: 70 mins

References
1. Blumberg, B.S. The Discovery of Australian Antigen and its Relation to Viral Hepatitis. Vitro. 1971;7:223.
2. Krugman, S. Glies J.P. Viral Hepatitis, Type B (MS-2-Strain). Further Observations on Natural History and Prevention. New England Journal of Medicine. 288, 755.
3. Krugman, S. Overby L.R, et al. Viral Hepatitis Type B Studies On Natural History and Prevention Re-examined. New England Journal of Medicine. 300, 101.

HCV ELISA

Hepatitis C Virus is a small, enveloped, positive-sense, single-stranded RNA Virus. HCV is now known to be the major cause of parenterally transmitted non-A, non-B hepatitis. HCV infection causes a wide variety of chronic liver disease, cirrhosis and liver cancer. The main route of transmission of the virus is via transfusion of blood and blood products, organ transplantation, and sharing contaminated needles and syringes.

Antibodies to HCV are found in over 80% of patients with welldocumented non-A, non-B hepatitis. Cloning the viral genome has made it possible to develop serologic assays that use recombinant antigens.1,2 Compared to the first generation HCV EIA tests using single recombinant antigen, new serologic tests incorporate recombinant protein and/or synthetic peptide antigens to avoid nonspecific cross-reactivity and to increase the sensitivity. 3, 4

The HCV Antibody EIA Test Kit is a third generation immunoassay for the qualitative detection of the presence of IgG antibodies to HCV in serum or plasma specimen. The test utilizes recombinant HCV antigens encoded by the genes for both structural (nucleocapsid) and non-structural proteins to selectively detect antibodies to HCV in serum or plasma.

Incubation Time: 70 mins

References
1. Choo, Q.L., G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton. Isolation of a cDNA Clone Derived from a Blood-borne Non-A, Non-B Viral Hepatitis Genome. Science. 1989;244:359.
2. Kuo, G., Q.L. Choo, H.J. Alter, and M. Houghton. An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis. Science. 1989;244:362.
3. Van der Poel, C. L., H.T.M. Cuypers, H.W. Reesink, and P.N.Lelie. Confirmation of Hepatitis C Virus Infection by New Four-antigen Recombinant Immunoblot Assay. Lancet. 1991;337:317.
4. Wilber, J.C. Development and Use of Laboratory Tests for Hepatitis C Infection: A Review. J. Clinical Immunoassay. 1993;16:204.

 

HIV 1/2/O Antibody EIA

HIV is the etiologic agent of Acquired Immune Deficiency Syndrome (AIDS). The main routes of transmission include exposure to blood and blood products including sharing needles and syringes, sexual contact, mother to child transmission. The virion is surrounded by a lipid envelope that is derived from the host cell membrane. Several viral glycoproteins are on the envelope. Each virus contains two copies of positive-sense genomic RNAs. HIV-1 has been isolated from patients with AIDS and AIDS-related complex, and from healthy people with high potential risk for developing AIDS.1 HIV-1 consists of Subtype M and Subtype O.

Highly divergent strains of HIV-1 were first recognized in 1990 and grouped provisionally as Subtype O as this variation has similar glycoprotein markers to HIV-1 but a slight variation to the protein marker. Although rarely compared to HIV-1 and HIV-2, infections caused by Subtype O have so far been identified in Africa (Cameroon), France and Germany. HIV-2 has been isolated from West African AIDS patients and from seropositive asymptomatic individuals.2 HIV-1, HIV-2, and Subtype O all elicit immune responses.3

Detection of HIV antibodies in serum, plasma or whole blood is the most efficient and common way to determine whether an individual has been exposed to HIV and to screen blood and blood products for HIV.4 Despite the differences in their biological characters, serological activities and genome sequences, HIV-1, HIV-2, and Subtype O show strong antigenic cross-reactivity.5,6 Most HIV-2 positive sera can be identified by using HIV-1 based serological tests.

The HIV 1/2/O Antibody EIA Test Kit is a third generation immunoassay for the qualitative detection of the presence of total antibodies (IgG, IgM and IgA) to HIV-1, HIV-2, and/or Subtype O in serum or plasma specimen. The test utilizes recombinant HIV antigens to selectively detect antibodies to HIV1, HIV-2 and/or Subtype O in serum or plasma.

Incubation Time: 60 mins

References
1. Chang, SY, Bowman, BH, Weiss, JB, Garcia, RE and White, TJ. The origin of HIV-1 isolate HTLVIIIB. Nature (1993) 3;363:466-9.
2. Arya, SK, Beaver, B, Jagodzinski, L, Ensoli, B, Kanki, PJ,Albert, J, Fenyo, EM, Biberfeld, G, Zagury, JF and Laure, F. New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (1987) 328:548-550.
3. Caetano JA Immunologic aspects of HIV infection. Acta Med Port (1991)
4 Suppl 1:52S-58S. 4. Janssen, RS, Satten, GA, Stramer, SL, Rawal, BD, O’Brien, TR, Weiblen, BJ, Hecht, FM, Jack, N, Cleghorn, FR, Kahn, JO, Chesney, MA and Busch MP. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 280(1):42-48.
5. Travers, K, Mboup, S, Marlink, R, Gueye-Nidaye, A, Siby, T, Thior, I, Traore, I, Dieng-Sarr, A, Sankale, JL and Mullins, C. Natural protection against HIV-1 infection provided by HIV-2. Science (1995) 268:1612-161.
6. Greenberg, AE, Wiktor, SZ, DeCock, KM, Smith, P, Jaffe HW and Dondero, TJ, Jr. HIV-2 and natural protection against HIV-1 infection. Science (1996) 272:1959-1960.

 

HIV 1/2/0 Antigen/Antibody ELISA 

The HIV-1 infection is identified by an early phase of antigenemia in which HIV-1 antigens (Ag) are detectable in blood. In most cases, antigen levels are often hard to detect; however, increased failure of the immune system and rising levels of the virus can re-stimulate detectable levels of antigen. The major internal structural protein of HIV-1, the core protein P24, is one of the viral components found in blood during antigenemia. Additionally, HIV-1 consists of Subtype M and Subtype O.

The HIV 1/2/O Antigen/Antibody EIA Test Kit is a fourth generation immunoassay for the qualitative detection of the presence of HIV-1 P24 antigen and total antibodies (IgG, IgM and IgA) to HIV-1, HIV-2, and/or Subtype O in serum or plasma specimen. The test utilizes HIV monoclonal antibodies and recombinant antigens to selectively detect HIV-1 P24 antigen and antibodies to HIV-1, HIV-2 and/or Subtype O in serum or plasma.

Incubation Time: 120 mins

 

Rapid Labs offer a wide range of ELISA tests for other infectious diseases and biomarkers. Our Compact ELISA range are designed to minimise freight charge thanks to their compact size. Our Specialist ELISA Kits covers a broader range of analytes with additional controls and calibrators, plus a longer shelf life than our Compact ELISA range.

View Compact ELISAs

View Specialist ELISA Kits